Pattern recognition receptor agonists in pathogen vaccines mediate antitumor T-cell cross-priming.

ABSTRACT:

Background

Cancer immunotherapies are generally effective in patients whose tumors contain a priori primed T-cells reactive to tumor antigens (TA). One approach to prime TA-reactive T-cells is to administer immunostimulatory molecules, cells, or pathogens directly to the tumor site, that is, in situ vaccination (ISV). We recently described an ISV using Flt3L to expand and recruit dendritic cells (DC), radiotherapy to load DC with TA, and pattern recognition receptor agonists (PRRa) to activate TA-loaded DC. While ISV trials using synthetic PRRa have yielded systemic tumor regressions, the optimal method to activate DCs is unknown.

Methods

To discover optimal DC activators and increase access to clinical grade reagents, we assessed whether viral or bacterial components

SUBMITTER: Aleynick M 

PROVIDER: S-EPMC10373699 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature